Toxicology – Phenytoin & Fosphenytoin Toxicity

Source

Phenytoin is an anticonvulsant used for seizure control. Fosphenytoin is a water-soluble prodrug of phenytoin that is commonly used intravenously because it is better tolerated.

Typical Presentation

A patient taking phenytoin may present with unsteady gait, slurred speech, lethargy, and altered mental status. Neurological findings usually become more pronounced as the serum concentration rises.

Clinical Features

Acute toxicity is dominated by neurological symptoms, including:

• Nystagmus
• Nausea and vomiting
• Ataxia and poor coordination
• Slurred speech
• Lethargy
• Extrapyramidal movements
• Altered mental status
• Coma in severe cases

IV phenytoin can also cause:

• Hypotension
• Ventricular dysrhythmias
• Cardiovascular collapse

Chronic therapy may be associated with:

• Gingival hyperplasia
• Coarsening of facial features
• Chronic ataxia
• Liver injury

Mechanism of Action

Phenytoin inhibits voltage-gated sodium channels in neurons, reducing repetitive neuronal firing. Excessive concentrations produce predominantly cerebellar and CNS dysfunction.

Management

Treatment is mainly supportive:

• Airway and respiratory support when necessary
• Neurological monitoring
• Cardiac monitoring after IV phenytoin toxicity
• Activated charcoal may be considered in appropriate recent oral exposures
• Manage hypotension, dysrhythmias, or other complications supportively

There is no specific antidote for phenytoin toxicity.

Key Points

• Nystagmus, ataxia, and slurred speech are classic findings of phenytoin toxicity.
• Neurological toxicity generally worsens as drug levels rise.
• IV phenytoin formulations can cause significant cardiovascular toxicity.
• Fosphenytoin is generally safer for IV administration because it does not contain the propylene glycol vehicle used in traditional IV phenytoin.
• IV phenytoin may cause severe local tissue injury, sometimes referred to as purple glove syndrome.

Toxicology – Carbamazepine Toxicity

Source

Carbamazepine is an anticonvulsant used for seizure disorders, trigeminal neuralgia, neuropathic pain, and bipolar disorder.

Typical Presentation

A patient, often after accidental or intentional ingestion, may develop marked drowsiness, unsteady gait, slurred speech, and altered mental status. Severe poisoning can progress to seizures, respiratory depression, coma, and cardiac conduction abnormalities.

Clinical Features

Possible findings include:

• Sedation and confusion
• Ataxia
• Dysarthria
• Nystagmus
• Anticholinergic features
• Respiratory depression
• Seizures
• Coma

ECG abnormalities may include:

• QRS widening
• QT prolongation
• Cardiac dysrhythmias in severe toxicity

Mechanism of Action

Carbamazepine blocks voltage-gated sodium channels, accounting for both its therapeutic anticonvulsant activity and many of its toxic effects. It is structurally related to tricyclic antidepressants and also has anticholinergic and sedating properties.

Management

Treatment is primarily supportive:

• Airway and respiratory support when needed
• Continuous cardiac monitoring and serial ECGs
• Benzodiazepines for seizures
• Sodium bicarbonate for clinically significant sodium-channel blockade with QRS widening
• Serial carbamazepine concentrations may be useful because absorption can be delayed and levels may continue to rise
• Multiple-dose activated charcoal may enhance elimination in selected significant poisonings
• Hemodialysis or hemoperfusion may be considered in severe or refractory toxicity with specialist guidance

Key Points

• Although carbamazepine treats seizures, overdose can itself cause seizures.
• Ataxia, nystagmus, sedation, and anticholinergic findings are common neurological clues.
• Sodium-channel blockade can produce dangerous cardiac conduction abnormalities.
• Chronic carbamazepine therapy may be associated with hyponatremia.

Toxicology – Monoamine Oxidase Inhibitor (MAOI) Toxicity

Source

Monoamine oxidase inhibitors are antidepressants now used mainly for atypical or treatment-resistant depression. Certain MAO-inhibiting drugs are also used in Parkinson disease.

Typical Presentation

A patient taking an MAOI may present with severe agitation, hypertension, sweating, tachycardia, and altered mental status. In overdose, symptoms can be significantly delayed and may later progress from a hyperadrenergic state to profound hypotension and cardiovascular collapse.

Clinical Features

MAOI toxicity can appear in several forms:

• Hyperadrenergic crisis: Headache, flushing, diaphoresis, dilated pupils, tachycardia, severe hypertension, and agitation. This may occur after consumption of high-tyramine foods while taking an MAOI.
• Acute overdose: Similar hyperadrenergic findings plus hyperthermia, vomiting, diarrhea, psychosis, myoclonus, seizures, and marked altered mental status. Severe cases may progress to coma, hypotension, and cardiovascular collapse.
• Serotonin syndrome: May occur when MAOIs are combined with other serotonergic medications and is characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity.

Symptoms after overdose may not appear for many hours and can persist for several days.

Mechanism of Action

MAOIs inhibit monoamine oxidase, the enzyme responsible for breaking down serotonin, norepinephrine, and dopamine. This causes accumulation of these neurotransmitters and excessive adrenergic and serotonergic activity.

Management

Treatment is primarily supportive:

• Airway and respiratory support when necessary
• Continuous cardiac and blood pressure monitoring
• Benzodiazepines for agitation and seizures
• Rapid cooling for significant hyperthermia
• Short-acting IV antihypertensive therapy may be required for severe hypertension
• IV fluids and vasopressors may be necessary if cardiovascular collapse develops
• Gastrointestinal decontamination may be considered in appropriate recent exposures

Because toxicity can be delayed, significant MAOI overdoses generally require prolonged monitored observation.

Key Points

• MAOI overdose can have a markedly delayed onset.
• Early toxicity often produces a hyperadrenergic state with hypertension and agitation.
• Severe poisoning may later progress to hypotension, coma, and cardiovascular collapse.
• Combining MAOIs with serotonergic drugs can precipitate serotonin syndrome.

Toxicology – Tricyclic Antidepressant (TCA) Toxicity

Source

Tricyclic antidepressants were once widely used for depression but are now also prescribed for conditions such as neuropathic pain, migraine prevention, OCD, and nocturnal enuresis. Examples include amitriptyline, clomipramine, desipramine, doxepin, imipramine, and nortriptyline.

Typical Presentation

A patient with TCA overdose may present with altered mental status, anticholinergic findings, seizures, hypotension, or ECG abnormalities, especially a widened QRS complex.

Clinical Features

Toxicity commonly affects the nervous and cardiovascular systems.

Anticholinergic findings:

• Dilated pupils
• Dry skin and mucous membranes
• Flushing
• Hyperthermia
• Tachycardia
• Urinary retention
• Confusion

Other important findings include:

• Sedation progressing to coma
• Seizures
• Orthostatic hypotension
• Cardiac arrhythmias

ECG abnormalities may include:

• Sinus tachycardia
• PR prolongation
• QRS widening
• QT prolongation
• Potentially fatal ventricular dysrhythmias

Mechanism of Action

TCAs have several pharmacologic actions, including:

• Anticholinergic activity
• Antihistamine effects
• α-adrenergic blockade
• Inhibition of serotonin and norepinephrine reuptake

Their most dangerous cardiac effect results from voltage-gated sodium channel blockade, which slows cardiac conduction and widens the QRS. Potassium-channel effects may also contribute to QT prolongation.

Management

Treatment requires rapid supportive care:

• Airway and respiratory support as needed
• Continuous cardiac monitoring and serial ECGs
• Benzodiazepines for seizures
• IV fluids for hypotension
• Sodium bicarbonate is the key therapy when significant QRS widening, ventricular dysrhythmias, or persistent hypotension is present
• Vasopressor support, typically norepinephrine, may be required if hypotension persists
• IV lipid emulsion may be considered in severe refractory toxicity with specialist guidance

Key Points

• QRS widening is an important marker of severe TCA toxicity.
• Increasing QRS duration is associated with a greater risk of seizures and ventricular arrhythmias.
• Cyclobenzaprine is structurally similar to TCAs and may produce a similar overdose pattern.
• Some TCAs, particularly desipramine, may produce prominent cardiotoxicity even without obvious anticholinergic findings.

 Toxicology – Bupropion Toxicity

Source

Bupropion is a prescription medication used primarily as an antidepressant and as an aid for smoking cessation. It is available in immediate-release and extended-release formulations.

Typical Presentation

A patient with excessive bupropion exposure may initially develop agitation and tachycardia before suddenly experiencing a generalized seizure. Extended-release formulations are particularly important because serious neurological and cardiovascular effects may be delayed.

Clinical Features

Possible manifestations include:

• Agitation and restlessness
• Sinus tachycardia
• Hypertension
• Nausea and vomiting
• Lethargy or altered mental status
• Orthostatic hypotension
• Seizures, which are a major feature of toxicity
• QRS widening
• QTc prolongation
• Cardiovascular instability in severe poisoning

Seizure risk increases with greater exposure, although seizures have occasionally been reported during therapeutic use.

Mechanism of Action

Bupropion primarily inhibits the reuptake of dopamine and norepinephrine, increasing their activity within the CNS. Its effects on dopamine are particularly prominent. The medication undergoes hepatic metabolism and has active metabolites that may contribute to prolonged toxicity.

Management

Treatment is primarily supportive:

• Maintain and protect the airway when necessary
• Continuous cardiac and neurological monitoring
• Benzodiazepines are first-line treatment for seizures
• Manage status epilepticus aggressively if it develops
• Monitor ECG for QRS and QT abnormalities
• Gastrointestinal decontamination may be considered in selected significant exposures
• Severe cardiovascular toxicity may require advanced toxicology-directed supportive therapies

Extended-release overdoses generally require prolonged observation because seizures and cardiovascular complications can occur after a substantial delay.

Key Points

• Seizures are a hallmark of bupropion toxicity.
• Extended-release preparations can produce delayed seizures.
• ECG abnormalities may include QRS widening and QTc prolongation.
• Severe poisoning can progress from agitation and tachycardia to seizures, altered consciousness, and cardiovascular collapse.

Toxicology – Selective Serotonin Reuptake Inhibitor (SSRI) Toxicity

Source

SSRIs are widely used to treat depression, anxiety disorders, and several other psychiatric conditions. Common agents include citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.

Typical Presentation

Most isolated SSRI overdoses cause only mild symptoms. Patients may present with nausea, vomiting, drowsiness, agitation, or changes in heart rate. More serious toxicity can occur with large exposures, certain agents, or when serotonin-enhancing drugs are combined.

Clinical Features

Possible effects include:

• Nausea and vomiting
• Tachycardia or bradycardia
• Drowsiness or agitation
• Ataxia
• Altered mental status
• Rarely, coma

Citalopram and escitalopram are particularly associated with QT prolongation and cardiac conduction abnormalities.

Severe serotonergic excess may cause serotonin syndrome, characterized by:

• Agitation or confusion
• Hyperreflexia, clonus, or muscle rigidity
• Tremor or myoclonus
• Tachycardia
• Diaphoresis
• Hyperthermia
• Nausea and vomiting
• Autonomic instability

Mechanism of Action

SSRIs inhibit serotonin reuptake, increasing serotonin concentrations and receptor stimulation within the central nervous system. Excessive serotonergic activity can produce serotonin syndrome.

Management

Treatment is primarily supportive:

• Airway and cardiorespiratory monitoring
• IV fluids when needed
• Benzodiazepines for agitation, tremor, or seizures
• Active cooling for significant hyperthermia
• Continuous ECG monitoring when cardiac toxicity is a concern
• Cyproheptadine may be considered in significant serotonin syndrome under specialist guidance

Severe serotonin syndrome may require intensive supportive care, including airway management and sedation.

Key Points

• Isolated SSRI overdoses are generally less cardiotoxic than tricyclic antidepressant or MAOI poisoning.
• Citalopram and escitalopram deserve particular attention because of their potential for QT prolongation.
• Serotonin syndrome is suggested by the combination of altered mental status, autonomic instability, and neuromuscular hyperactivity.
• Clinical observation and ECG findings help determine the appropriate duration of monitoring.

Toxicology – Imidazoline Poisoning

Source

Imidazolines are found in many over-the-counter eye drops and nasal decongestants. Examples include tetrahydrozoline, oxymetazoline, naphazoline, and xylometazoline. Clonidine is pharmacologically related to this group.

Typical Presentation

After accidental or intentional ingestion of an imidazoline-containing product, a patient may rapidly become drowsy, hypotensive, or unconscious. Severe poisoning can resemble clonidine toxicity with marked CNS and respiratory depression.

Clinical Features

Oral exposure may produce:

• Drowsiness and CNS depression
• Hypotension
• Bradycardia or other heart-rate abnormalities
• Nausea and vomiting
• Syncope
• Hypothermia
• Respiratory depression or apnea
• Seizures
• Coma

A brief period of hypertension may occur early because of peripheral vasoconstriction.

Mechanism of Action

Imidazolines stimulate α-adrenergic receptors. Their topical action produces vasoconstriction, which explains their effectiveness as decongestants. After systemic absorption, central α2-adrenergic effects reduce sympathetic activity, producing CNS depression, bradycardia, and hypotension.

Management

There is no established specific antidote, so treatment is primarily supportive:

• Maintain the airway and assist ventilation when necessary
• Monitor cardiac rhythm and blood pressure
• Give IV fluids for clinically significant hypotension
• Vasopressors may be required for persistent cardiovascular instability
• Early hypertension is usually temporary and often does not require treatment
• Gastrointestinal decontamination may be considered in selected recent exposures

Key Points

• Ingestion of topical eye or nasal decongestants can cause serious systemic poisoning.
• The clinical picture can closely resemble clonidine toxicity.
• Severe cases may cause profound CNS and respiratory depression.
• Chronic excessive use of topical nasal decongestants can cause rebound congestion (rhinitis medicamentosa).

Medicine – Cerebrovascular Disease

Cerebrovascular disease refers to disorders affecting the blood vessels supplying the brain. The two major clinical syndromes are transient ischaemic attack (TIA) and stroke.

A stroke may be caused by ischaemia from arterial occlusion or by intracranial haemorrhage. Rapid recognition is essential because some treatments are highly time-dependent.

1. Transient Ischaemic Attack

A transient ischaemic attack (TIA) is a temporary episode of focal neurological dysfunction caused by cerebral, spinal cord, or retinal ischaemia without acute infarction.

The older definition used:

Complete recovery within 24 hours.

Modern practice is more tissue-based rather than purely time-based.

Most TIAs actually resolve within:

Minutes to less than 1 hour.

2. Mechanism of TIA

TIAs are usually caused by transient interruption of blood flow.

Mechanisms include:

Artery-to-artery embolism.

Cardioembolism.

Small-vessel disease.

Critical arterial stenosis with transient hypoperfusion.

Therefore, embolism is important but is not the only mechanism.

3. Clinical Importance of TIA

A TIA is a major warning sign for future stroke.

The risk is particularly high:

In the first hours and days after the event.

Therefore, a patient with suspected TIA requires urgent assessment and secondary prevention.

4. Stroke

A stroke, traditionally called cerebrovascular accident or CVA, is an acute neurological deficit caused by:

Cerebral infarction.

or

Intracranial haemorrhage.

Unlike a TIA, stroke produces persistent neurological dysfunction and/or demonstrable brain tissue injury.

5. Main Types of Stroke

Stroke can be divided into:

Ischaemic stroke.

and

Haemorrhagic stroke.

Ischaemic stroke is more common.

6. Ischaemic Stroke

Ischaemic stroke occurs when an artery supplying the brain becomes occluded.

Important mechanisms include:

Cardioembolism.

Large-artery atherosclerotic thrombosis or embolism.

Small-vessel occlusion.

Other less common causes such as dissection or vasculitis.

7. Cardioembolic Stroke

Important cardiac sources include:

Atrial fibrillation.

Recent myocardial infarction with ventricular thrombus.

Mechanical heart valves.

Mitral stenosis with atrial thrombus.

Infective endocarditis.

Atrial fibrillation is one of the most important causes.

8. Large-Artery Atherosclerotic Stroke

Atherosclerosis of major arteries can cause:

Local thrombosis.

or

Artery-to-artery embolism.

The carotid arteries are particularly important in anterior-circulation stroke.

9. Haemorrhagic Stroke

Haemorrhagic stroke includes:

Intracerebral haemorrhage.

and, in broader cerebrovascular disease discussions,

Subarachnoid haemorrhage.

Common causes of intracerebral haemorrhage include:

Hypertension.

Cerebral amyloid angiopathy.

Anticoagulation.

Vascular malformations.

Tumours.

10. Clinical Presentation of Stroke

Stroke classically causes:

Sudden-onset focal neurological deficit.

Possible symptoms include:

Weakness.

Sensory loss.

Speech disturbance.

Visual loss.

Diplopia.

Ataxia.

Vertigo.

Dysphagia.

The exact pattern depends on the vascular territory involved.

11. Anterior Circulation Stroke

Anterior circulation strokes involve the:

Internal carotid artery system.

This includes the:

Middle cerebral artery.

and

Anterior cerebral artery.

12. Contralateral Weakness and Sensory Loss

Anterior circulation stroke commonly produces:

Contralateral motor weakness.

and/or

Contralateral sensory loss.

The face, arm, and leg may be involved to different degrees depending on the vessel.

13. Middle Cerebral Artery Pattern

A typical middle cerebral artery stroke may cause:

Contralateral face and arm weakness greater than leg weakness.

Contralateral sensory loss.

Aphasia if the dominant hemisphere is affected.

Neglect if the non-dominant hemisphere is affected.

Homonymous hemianopia.

14. Anterior Cerebral Artery Pattern

Anterior cerebral artery stroke more often causes:

Contralateral leg weakness greater than arm weakness.

It may also produce:

Behavioural change.

Abulia.

Urinary incontinence.

because medial frontal structures may be involved.

15. Amaurosis Fugax

Amaurosis fugax is transient monocular visual loss caused by retinal ischaemia.

It is often described as:

A curtain descending over one eye.

It usually reflects embolic disease from the ipsilateral carotid circulation.

16. Homonymous Hemianopia

A homonymous hemianopia affects the same side of the visual field in both eyes.

For example:

Right homonymous hemianopia → left retrochiasmal lesion.

It may occur with lesions of:

Optic tract.

Optic radiations.

Occipital cortex.

17. Aphasia

Aphasia indicates dysfunction of the dominant cerebral hemisphere, usually the left hemisphere.

Possible forms include:

Expressive aphasia.

Receptive aphasia.

Global aphasia.

Aphasia is particularly associated with dominant middle cerebral artery stroke.

18. Dysarthria

Dysarthria is impaired articulation of speech due to motor dysfunction.

Unlike aphasia:

Language formulation and comprehension may remain intact.

Dysarthria can occur with cortical, subcortical, brainstem, or cerebellar stroke.

19. Posterior Circulation Stroke

Posterior circulation stroke involves the:

Vertebral arteries.

Basilar artery.

Posterior cerebral arteries.

It supplies the:

Brainstem.

Cerebellum.

Occipital lobes.

20. Crossed Neurological Signs

Brainstem stroke may produce:

Ipsilateral cranial nerve deficits

with

Contralateral limb weakness or sensory loss.

This is a classic “crossed” pattern.

For example:

Ipsilateral facial sensory abnormality + contralateral limb sensory abnormality.

21. Posterior Circulation Symptoms

Important symptoms include:

Vertigo.

Diplopia.

Dysarthria.

Dysphagia.

Ataxia.

Nystagmus.

Visual field loss.

Limb weakness or sensory loss.

22. Visual Loss in Posterior Circulation Stroke

Posterior cerebral artery infarction may produce:

Contralateral homonymous hemianopia.

Bilateral occipital involvement can produce profound visual loss.

23. Cerebellar Stroke

Cerebellar stroke may cause:

Severe vertigo.

Vomiting.

Gait or truncal ataxia.

Limb incoordination.

Nystagmus.

A patient may have severe inability to stand or walk even without major limb weakness.

24. Basilar Artery Occlusion

Basilar artery occlusion is a neurological emergency.

Possible features include:

Quadriparesis.

Cranial nerve abnormalities.

Reduced consciousness.

Dysarthria.

Dysphagia.

Locked-in syndrome.

25. Lacunar Infarctions

Lacunar infarcts are small subcortical infarctions caused by occlusion of small penetrating arteries.

They are strongly associated with:

Chronic hypertension.

Diabetes mellitus.

Small-vessel lipohyalinosis.

26. Pure Motor Stroke

A classic lacunar syndrome is:

Pure motor hemiparesis.

A common lesion site is:

Posterior limb of the internal capsule.

Other sites can include the:

Pons.

Corona radiata.

27. Pure Sensory Stroke

Another classic lacunar syndrome is:

Pure sensory stroke.

The typical site is the:

Thalamus.

This may produce numbness or altered sensation affecting one side of the body.

28. Other Lacunar Syndromes

Other important lacunar syndromes include:

Ataxic hemiparesis.

Dysarthria–clumsy hand syndrome.

These can help localise small-vessel subcortical infarction.

29. Diagnosis

Stroke diagnosis begins with:

Clinical assessment.

The first goals are to determine:

Is this a stroke?

Is it ischaemic or haemorrhagic?

When was the patient last known well?

Is reperfusion therapy possible?

30. Immediate Brain Imaging

Urgent brain imaging is essential.

The initial study is commonly:

Non-contrast CT brain.

Its main immediate purpose is to identify:

Intracranial haemorrhage.

It may also show early signs of ischaemia.

31. MRI Brain

MRI, particularly diffusion-weighted imaging, is highly sensitive for:

Acute cerebral infarction.

It can be especially useful in:

Posterior circulation stroke.

Small infarcts.

Diagnostic uncertainty.

32. CT Angiography

Modern acute stroke assessment often includes:

CT angiography.

This can identify:

Large-vessel occlusion.

Carotid disease.

Intracranial arterial stenosis or occlusion.

This is particularly important when considering mechanical thrombectomy.

33. Blood Pressure Assessment

Blood pressure should be measured because hypertension is:

A major stroke risk factor.

and

An important consideration in acute treatment decisions.

Acute blood pressure management depends on whether the stroke is ischaemic or haemorrhagic and whether thrombolysis is planned.

34. ECG

ECG is performed to look for:

Atrial fibrillation.

Other cardiac abnormalities may also suggest an embolic source.

Because paroxysmal AF may be missed on a single ECG, longer cardiac rhythm monitoring may be required.

35. Lipids

A lipid profile helps identify:

Dyslipidaemia.

This supports vascular risk assessment and guides lipid-lowering therapy.

36. Glucose

Blood glucose is checked because:

Hypoglycaemia can mimic stroke.

Hyperglycaemia is also associated with poorer outcomes in acute stroke.

Therefore:

Always check glucose early.

37. ESR and CRP

Inflammatory markers such as:

ESR.

CRP.

may be useful when there is suspicion of:

Giant cell arteritis.

Vasculitis.

Inflammatory or infectious disease.

They are not routine diagnostic markers for every stroke.

38. Thrombophilia Testing

The older note suggests thrombophilia screening in everyone under 45.

Modern practice is more selective.

Testing may be considered in:

Young patients with unexplained stroke.

especially when there is:

Venous thrombosis.

Pregnancy-related thrombosis.

Recurrent thrombosis.

Strong family history.

Suspected antiphospholipid syndrome.

Routine broad thrombophilia screening is not necessary for every young stroke patient.

39. Carotid Imaging

Carotid imaging is important after:

Anterior circulation TIA or ischaemic stroke.

It may be performed with:

Carotid Doppler ultrasound.

CT angiography.

MR angiography.

The purpose is to identify significant carotid stenosis.

40. Echocardiography

Echocardiography may be used to identify a cardiac embolic source.

Possible abnormalities include:

Mural thrombus.

Valvular disease.

Intracardiac tumour.

Patent foramen ovale in selected patients.

41. Transoesophageal Echocardiography

TOE gives improved visualisation of structures such as:

Left atrium and atrial appendage.

Aortic arch.

Interatrial septum.

It can be useful when the embolic source remains uncertain.

42. Acute Stroke Unit Care

Patients with acute stroke should ideally be managed in a:

Dedicated stroke unit.

Stroke-unit care improves outcomes through organised multidisciplinary management.

43. Hydration

Adequate hydration is important.

However, fluid therapy should be:

Carefully controlled.

Excess free water should be avoided, and hypotonic fluids are generally not preferred.

44. Swallow Assessment

Every acute stroke patient should have:

Swallow screening before oral food, fluids, or medication.

If swallowing is unsafe:

Keep nil by mouth initially.

This reduces the risk of:

Aspiration pneumonia.

45. Hyperglycaemia

Marked hyperglycaemia should be treated appropriately.

However, overly aggressive glucose lowering can cause hypoglycaemia.

The goal is generally:

Avoid severe hyperglycaemia and avoid hypoglycaemia.

Routine insulin for every patient is not required.

46. Fever

Fever should be investigated and treated because it may worsen neurological injury.

Paracetamol can be used for:

Pyrexia.

The underlying cause, such as infection, should also be sought.

47. DVT Prophylaxis

Immobile stroke patients are at increased risk of:

Deep vein thrombosis.

Pulmonary embolism.

Mechanical prophylaxis, particularly:

Intermittent pneumatic compression, may be used.

Pharmacological prophylaxis depends on bleeding risk and stroke type.

48. Rehabilitation

Early rehabilitation is important.

This may involve:

Physiotherapy.

Occupational therapy.

Speech and language therapy.

Swallowing therapy.

Neuropsychology.

Social support.

49. Aspirin in Ischaemic Stroke

Once intracranial haemorrhage has been excluded, aspirin is commonly given in acute ischaemic stroke when thrombolysis-related timing and contraindications permit.

It reduces the risk of:

Early recurrent ischaemic events.

50. Modern Antiplatelet Therapy

The older sequence of aspirin, then dipyridamole, then clopidogrel is outdated.

For long-term secondary prevention of non-cardioembolic stroke, common options include:

Clopidogrel monotherapy.

or

Aspirin-based therapy depending on local guidance and patient factors.

51. Dual Antiplatelet Therapy

For selected patients with:

High-risk TIA

or

Minor ischaemic stroke,

short-term dual antiplatelet therapy with:

Aspirin + clopidogrel

may be used for a limited period, followed by single antiplatelet therapy.

It is not used indefinitely because bleeding risk rises.

52. Intravenous Thrombolysis

The older note states thrombolysis within:

3 hours.

Modern treatment windows are broader in selected patients.

Intravenous thrombolysis may be considered up to approximately:

4.5 hours from symptom onset

in eligible patients, with some imaging-selected exceptions beyond this in specialist protocols.

53. Thrombolytic Drugs

A commonly used thrombolytic is:

Alteplase.

In some systems:

Tenecteplase

is also used.

The goal is to dissolve the clot and restore blood flow.

54. Mechanical Thrombectomy

A major modern addition is:

Mechanical thrombectomy.

This is used for selected patients with:

Large-vessel occlusion.

A catheter device is used to physically remove the clot.

55. Thrombectomy Time Window

Mechanical thrombectomy is most effective when performed early.

However, selected patients may benefit:

Up to 24 hours from last known well

when advanced imaging demonstrates salvageable brain tissue and appropriate vessel occlusion.

56. Blood Pressure in Acute Ischaemic Stroke

The older note says to treat hypertension 2 weeks after CVA.

This is too simplistic.

In acute ischaemic stroke:

Blood pressure is often allowed to remain moderately elevated initially because aggressive lowering can reduce cerebral perfusion.

However, blood pressure may need urgent treatment if:

Thrombolysis is planned.

There is severe hypertension.

There is another hypertensive emergency.

Long-term BP control should begin once clinically appropriate.

57. Smoking Cessation

Smoking substantially increases vascular risk.

Therefore:

Smoking cessation is an important component of secondary prevention.

58. Statins

Statin therapy is commonly used after ischaemic stroke or TIA of atherosclerotic origin.

Statins reduce:

LDL cholesterol.

Future stroke risk.

Other cardiovascular events.

59. Anticoagulation in Atrial Fibrillation

If stroke or TIA is caused by atrial fibrillation, long-term prevention usually requires:

Oral anticoagulation.

Modern treatment commonly uses:

Direct oral anticoagulants, DOACs

for non-valvular AF when appropriate.

60. Timing of Anticoagulation

The older rule of “2 weeks after infarct” is too rigid.

The timing depends on:

Infarct size.

Stroke severity.

Haemorrhagic transformation.

Bleeding risk.

Cardioembolic risk.

Smaller strokes may permit earlier anticoagulation, while large infarcts often require a longer delay.

61. TIA and Anticoagulation

After a TIA caused by atrial fibrillation, anticoagulation may often be started:

Early, once intracranial bleeding has been excluded and no contraindication exists.

62. Mitral Stenosis and Mural Thrombus

Anticoagulation may also be indicated with:

Mitral stenosis and atrial fibrillation.

Intracardiac mural thrombus.

Mechanical heart valves.

The precise anticoagulant depends on the cardiac condition.

63. Carotid Endarterectomy

Carotid endarterectomy can reduce recurrent stroke risk in selected patients with:

Symptomatic carotid stenosis.

The older threshold of >80% is too restrictive.

Benefit is strongest in:

Severe symptomatic stenosis, especially 70–99%.

Selected patients with:

50–69% stenosis

may also benefit depending on age, sex, surgical risk, and timing.

64. Timing of Carotid Surgery

When indicated, carotid endarterectomy is generally most beneficial when performed:

Soon after the TIA or non-disabling stroke, once the patient is medically stable.

Early treatment reduces the period of highest recurrent stroke risk.

65. Haemorrhagic Stroke Management

Management of intracerebral haemorrhage focuses on:

Blood pressure control.

Reversal of anticoagulation if appropriate.

Management of raised intracranial pressure.

Neurosurgical assessment when indicated.

Treatment of complications.

66. Neurosurgery in Haemorrhagic Stroke

Neurosurgery may be considered in selected cases such as:

Cerebellar haemorrhage with compression.

Hydrocephalus.

Certain superficial lobar haemorrhages.

Deteriorating neurological state.

Not every intracerebral haemorrhage requires surgery.

67. Blood Pressure in Intracerebral Haemorrhage

Unlike many acute ischaemic strokes, intracerebral haemorrhage often requires:

Earlier controlled blood-pressure reduction.

The goal is to reduce haematoma expansion while avoiding cerebral hypoperfusion.

68. Prognosis

Stroke remains a major cause of:

Death.

Long-term disability.

Cognitive impairment.

Epilepsy.

Depression.

Loss of independence.

Outcome depends greatly on stroke type, size, location, age, initial severity, and treatment speed.

69. Mortality

The older estimate of:

20–30% mortality

is too broad to apply universally.

Mortality varies substantially between:

Minor ischaemic stroke.

Large-vessel ischaemic stroke.

Intracerebral haemorrhage.

Subarachnoid haemorrhage.

Haemorrhagic strokes generally have higher early mortality.

70. Long-Term Disability

A substantial proportion of stroke survivors remain functionally impaired.

Possible residual deficits include:

Weakness.

Aphasia.

Dysphagia.

Visual field loss.

Cognitive impairment.

Gait problems.

Depression.

Loss of independence.

Early rehabilitation can significantly improve outcome.

71. TIA – Note Form

Definition:

Transient focal neurological dysfunction caused by ischaemia without acute infarction.

Old rule:

Symptoms resolve within 24 hours.

Modern reality:

Most resolve within minutes to less than 1 hour.

Importance:

Strong warning sign for subsequent stroke.

72. Stroke – Note Form

Ischaemic stroke:

Arterial occlusion → cerebral infarction.

Haemorrhagic stroke:

Intracranial bleeding.

Main ischaemic mechanisms:

Cardioembolism.

Large-artery atherosclerosis.

Small-vessel disease.

Other causes such as dissection or vasculitis.

73. Anterior Circulation – Note Form

Contralateral face/arm/leg weakness or sensory loss.

Ipsilateral monocular visual loss.

Homonymous hemianopia.

Aphasia if dominant hemisphere.

Neglect if non-dominant hemisphere.

Dysarthria may occur.

74. Posterior Circulation – Note Form

Vertigo.

Diplopia.

Dysarthria.

Dysphagia.

Ataxia.

Nystagmus.

Homonymous visual field loss.

Ipsilateral cranial nerve signs with contralateral limb signs may occur.

75. Lacunar Stroke – Note Form

Cause:

Occlusion of small penetrating arteries.

Risk factors:

Hypertension.

Diabetes.

Pure motor hemiparesis:

Posterior limb of internal capsule.

Pure sensory stroke:

Thalamus.

76. Acute Investigation – Note Form

Check glucose immediately.

Urgent non-contrast CT brain.

MRI if needed.

CT angiography for large-vessel occlusion.

ECG for AF.

BP.

Lipids.

Glucose/HbA1c.

Carotid imaging when appropriate.

Echocardiography for suspected cardiac embolic source.

77. Acute Ischaemic Stroke Treatment – Note Form

Stroke unit care.

Swallow assessment before oral intake.

Hydration.

Treat fever and major glucose disturbance.

DVT prevention.

Early rehabilitation.

Antiplatelet therapy after haemorrhage excluded.

IV thrombolysis in eligible patients, generally up to about 4.5 hours.

Mechanical thrombectomy for selected large-vessel occlusion, sometimes up to 24 hours with imaging selection.

78. Secondary Prevention – Note Form

Stop smoking.

Control blood pressure.

Treat diabetes.

Statin therapy when appropriate.

Antiplatelet therapy for non-cardioembolic disease.

Anticoagulation for AF or other cardioembolic indications.

Carotid endarterectomy for appropriate symptomatic carotid stenosis.

79. Haemorrhagic Stroke – Note Form

Control blood pressure.

Reverse anticoagulation when indicated.

Manage raised intracranial pressure.

Neurosurgical assessment if appropriate.

80. Important Corrections to the Original Notes

TIA = not simply “<24 hours.” Modern definition is tissue-based and requires no acute infarction.

TIA is not caused only by emboli. It can also result from small-vessel disease or transient hypoperfusion.

Thrombolysis is not limited to 3 hours. Standard IV treatment may extend to about 4.5 hours in eligible patients.

Mechanical thrombectomy is a major modern treatment for large-vessel occlusion and may be possible in selected patients up to 24 hours.

Dipyridamole as “second line after aspirin failure” is outdated. Modern antiplatelet choice is more individualised, with clopidogrel commonly used.

Anticoagulation timing after stroke is not always 2 weeks. It depends on infarct size and bleeding risk.

Carotid endarterectomy is not restricted to >80% stenosis. Greatest benefit is in symptomatic 70–99%, with selected benefit in 50–69%.

Treating hypertension after stroke is more nuanced than waiting 2 weeks. Acute management depends on stroke type, blood pressure level, and reperfusion treatment.

Key Clinical Pattern

Think of cerebrovascular disease as:

TIA = TEMPORARY FOCAL ISCHAEMIC DEFICIT WITHOUT INFARCTION.

STROKE = PERSISTENT DEFICIT FROM INFARCTION OR HAEMORRHAGE.

For localisation:

ANTERIOR CIRCULATION → CONTRALATERAL WEAKNESS/SENSORY LOSS ± APHASIA ± MONOCULAR VISUAL LOSS.

POSTERIOR CIRCULATION → VERTIGO + DIPLOPIA + DYSPHAGIA + DYSARTHRIA + ATAXIA ± CROSSED SIGNS.

For lacunar stroke:

PURE MOTOR → INTERNAL CAPSULE.

PURE SENSORY → THALAMUS.

For acute management:

CT FIRST → ISCHAEMIC OR HAEMORRHAGIC?

Then consider:

THROMBOLYSIS ± THROMBECTOMY for eligible ischaemic stroke.

And for prevention:

ANTIPLATELET or ANTICOAGULATION + STATIN + BP CONTROL + SMOKING CESSATION + CAROTID TREATMENT WHEN INDICATED.

Medicine – Autonomic Neuropathy

Autonomic neuropathy is dysfunction of the autonomic nervous system caused by damage to sympathetic and/or parasympathetic nerve fibres. It can affect cardiovascular control, pupils, sweating, gastrointestinal motility, bladder function, and sexual function.

An asterisk (*) signifies a common cause.

1. Postural Hypotension

One of the most important manifestations is postural, or orthostatic, hypotension.

Normally, standing causes reflex sympathetic vasoconstriction and an increase in heart rate to maintain blood pressure.

In autonomic neuropathy, this response is impaired, so blood pressure may fall on standing.

Patients may experience:

Dizziness.

Light-headedness.

Blurred vision.

Weakness.

Syncope.

2. Impaired Cardiovascular Reflexes

Autonomic neuropathy can cause loss of normal cardiovascular responses to changes in posture, breathing, and exertion.

Abnormalities may include:

Reduced heart-rate variability.

Blunted heart-rate response to deep breathing.

Impaired response to standing.

Poor blood-pressure compensation during posture change.

These findings are especially important in diabetic autonomic neuropathy.

3. Pupillary Abnormalities

The original note refers to a sluggish or absent pupillary light response.

Autonomic dysfunction can interfere with both sympathetic and parasympathetic control of the pupil.

Possible abnormalities include:

Sluggish pupillary constriction.

Impaired dilation in darkness.

Small pupils or abnormal pupil size responses.

However, a completely absent light reflex is not a universal feature of autonomic neuropathy and should prompt consideration of additional ocular or neurological causes.

4. Anhidrosis

Anhidrosis means reduced or absent sweating.

Sweat glands are controlled primarily by sympathetic autonomic fibres.

Damage to these fibres may produce:

Reduced sweating.

Patchy anhidrosis.

Heat intolerance.

Dry skin.

Some patients may develop compensatory excessive sweating in unaffected areas.

5. Defective Piloerection

Piloerection, or “goose bumps,” is mediated by sympathetic fibres supplying the arrector pili muscles.

Autonomic neuropathy may impair this response.

Although this is physiologically characteristic, it is usually less clinically important than cardiovascular, gastrointestinal, bladder, or sexual dysfunction.

6. Erectile Dysfunction

Autonomic nerve damage can impair sexual function.

In men, one important manifestation is:

Erectile dysfunction.

Normal erection requires intact parasympathetic pathways, while ejaculation depends significantly on sympathetic pathways.

Autonomic neuropathy may therefore cause:

Difficulty achieving erection.

Difficulty maintaining erection.

Ejaculatory abnormalities.

7. Bladder Dysfunction

Autonomic neuropathy can interfere with bladder filling, sensation, and emptying.

Patients may develop:

Reduced awareness of bladder fullness.

Poor detrusor contraction.

Urinary retention.

Overflow incontinence.

Incomplete bladder emptying.

Therefore, the original term “urinary incontinence” is only part of the picture.

In autonomic neuropathy, retention with overflow incontinence is often particularly important.

8. Nocturnal Diarrhoea

Autonomic dysfunction of the gastrointestinal tract can cause abnormal intestinal motility.

A classic feature in diabetic autonomic neuropathy is:

Nocturnal diarrhoea.

It may be intermittent and can sometimes alternate with constipation.

Other causes of diarrhoea should still be excluded.

9. Constipation

Reduced autonomic control of bowel motility can produce:

Slow intestinal transit.

Constipation.

Patients may also have alternating episodes of constipation and diarrhoea.

10. Gastroparesis

An important gastrointestinal manifestation not listed in the original note is gastroparesis.

This is delayed gastric emptying due to autonomic dysfunction.

Patients may develop:

Early satiety.

Postprandial fullness.

Nausea.

Vomiting.

Abdominal bloating.

In diabetes, gastroparesis can also make glucose control more difficult.

11. Diabetes Mellitus*

Diabetes mellitus is one of the most common causes of autonomic neuropathy.

Long-standing hyperglycaemia damages peripheral autonomic fibres.

Diabetic autonomic neuropathy may involve several systems at the same time.

12. Cardiovascular Autonomic Neuropathy in Diabetes

Diabetic autonomic neuropathy may cause:

Resting tachycardia.

Reduced heart-rate variability.

Orthostatic hypotension.

Reduced exercise-related cardiovascular responses.

More advanced cardiovascular autonomic dysfunction is associated with increased clinical risk.

13. Gastrointestinal Autonomic Neuropathy in Diabetes

Diabetic autonomic dysfunction may produce:

Gastroparesis.

Constipation.

Nocturnal diarrhoea.

Faecal incontinence in severe cases.

These abnormalities can reflect disturbed autonomic control throughout the gastrointestinal tract.

14. Genitourinary Autonomic Neuropathy in Diabetes

Possible manifestations include:

Erectile dysfunction.

Bladder atony.

Urinary retention.

Overflow incontinence.

Incomplete bladder emptying.

Recurrent urinary tract infection may occur when residual urine remains in the bladder.

15. Guillain–Barré Syndrome

Guillain–Barré syndrome can produce marked autonomic dysfunction because autonomic peripheral nerve fibres may be affected.

Possible manifestations include:

Blood-pressure fluctuations.

Tachycardia.

Bradycardia.

Cardiac arrhythmias.

Urinary retention.

Ileus.

Abnormal sweating.

Severe autonomic instability is one reason why patients with GBS require careful monitoring.

16. Amyloidosis

Amyloidosis can cause a progressive peripheral neuropathy with prominent autonomic involvement.

Patients may develop:

Postural hypotension.

Diarrhoea or constipation.

Erectile dysfunction.

Bladder dysfunction.

Sweating abnormalities.

Hereditary transthyretin amyloidosis is particularly well known for producing a mixed sensory, motor, and autonomic neuropathy.

17. Porphyria

Acute hepatic porphyrias can affect peripheral and autonomic nerves.

During attacks, patients may develop:

Abdominal pain.

Peripheral motor neuropathy.

Autonomic instability.

Tachycardia.

Hypertension.

Constipation.

Urinary symptoms.

Neuropsychiatric manifestations may also occur.

18. Multiple System Atrophy

Multiple system atrophy, MSA, is a progressive neurodegenerative disorder associated with severe autonomic failure.

Older terminology includes:

Shy–Drager syndrome.

This term is now largely historical.

19. Autonomic Features of Multiple System Atrophy

Patients may develop:

Severe orthostatic hypotension.

Urinary urgency or retention.

Erectile dysfunction.

Abnormal sweating.

These autonomic abnormalities may occur together with:

Parkinsonism.

or

Cerebellar dysfunction.

20. Multiple System Atrophy and Parkinsonism

MSA can resemble Parkinson disease but often has important distinguishing features.

These include:

Early and severe autonomic dysfunction.

Poor or limited levodopa response.

Early postural instability.

Cerebellar signs in some patients.

Stridor in some advanced cases.

Therefore:

Parkinsonism + prominent early autonomic failure → consider MSA.

21. Other Causes

Other possible causes of autonomic neuropathy include:

Autoimmune autonomic ganglionopathy.

Certain peripheral neuropathies.

Toxic or drug-induced neuropathy.

Paraneoplastic disease.

Hereditary neuropathies.

Spinal cord or brainstem disorders, depending on the pattern.

The underlying cause should be sought when autonomic dysfunction is clinically significant.

22. Investigation

Investigation depends on the suspected cause.

Useful assessments may include:

Lying and standing blood pressure.

Heart-rate response to standing.

Heart-rate variability during deep breathing.

ECG.

Blood glucose and HbA1c.

Nerve conduction studies where peripheral neuropathy is suspected.

Bladder residual-volume assessment.

Autonomic function testing in specialist centres.

23. Orthostatic Blood Pressure Testing

Blood pressure is measured after lying down and again after standing.

A significant fall supports orthostatic hypotension.

The clinical interpretation should also consider medications, dehydration, blood loss, and other cardiovascular causes because not all postural hypotension is due to neuropathy.

24. Treatment

Management involves treating the underlying cause and controlling individual autonomic symptoms.

For example:

Improved diabetic control may help reduce progression.

Adequate hydration and medication review may improve orthostatic symptoms.

Bladder dysfunction may require scheduled voiding or catheterisation in selected patients.

Gastroparesis and bowel dysfunction require targeted treatment.

Erectile dysfunction can be treated when appropriate.

Management is therefore usually symptom-specific.

25. Autonomic Neuropathy – Note Form

Definition: dysfunction of sympathetic and/or parasympathetic peripheral nerves.

Cardiovascular: postural hypotension, resting tachycardia and impaired cardiovascular reflexes.

Pupils: sluggish autonomic pupillary responses may occur.

Sweating: anhidrosis or abnormal sweating.

Piloerection: may be impaired.

Sexual function: erectile dysfunction is common in some causes.

Bladder: reduced bladder sensation, retention and overflow incontinence.

Gastrointestinal: gastroparesis, nocturnal diarrhoea and constipation.

*Common cause: ** diabetes mellitus.

Acute cause: Guillain–Barré syndrome.

Infiltrative cause: amyloidosis.

Metabolic/toxic neurological cause: porphyria.

Neurodegenerative cause: multiple system atrophy.

26. Useful Clinical Associations

Autonomic neuropathy + long-standing diabetes → diabetic autonomic neuropathy.

Autonomic instability + ascending weakness + areflexia → Guillain–Barré syndrome.

Autonomic failure + sensory neuropathy + systemic features → consider amyloidosis.

Autonomic symptoms + severe abdominal pain + motor neuropathy → consider acute porphyria.

Early severe autonomic failure + parkinsonism/cerebellar signs → consider multiple system atrophy.

Key Clinical Pattern

Think of autonomic neuropathy as dysfunction affecting:

BLOOD PRESSURE + PUPILS + SWEATING + GUT + BLADDER + SEXUAL FUNCTION.

The classic features are:

Postural hypotension + anhidrosis + erectile dysfunction + bladder dysfunction + nocturnal diarrhoea/constipation + impaired cardiovascular reflexes.

The most important common cause is:

Diabetes mellitus.

Other high-yield causes are:

Guillain–Barré syndrome + amyloidosis + porphyria + multiple system atrophy.

Medicine – Guillain–Barré Syndrome (Acute Inflammatory Demyelinating Polyneuropathy)

Guillain–Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that typically causes rapidly progressive, symmetrical weakness with reduced or absent reflexes. The most common form in many regions is acute inflammatory demyelinating polyneuropathy (AIDP), although other axonal variants also exist.

It is often triggered by a recent infection, but the neurological illness itself is not usually due to direct infection of the nerves. Instead, it results from an abnormal immune response directed against components of the peripheral nervous system.

1. Basic Mechanism

GBS is best regarded as an autoimmune inflammatory neuropathy rather than simply an “acute infective polyneuropathy.”

A preceding infection may stimulate the immune system to produce antibodies that cross-react with peripheral nerve components through a process known as molecular mimicry.

This immune response can damage:

Peripheral nerve myelin.

Nerve roots.

Axons in some variants.

2. Peripheral Rather Than Central Nervous System Disease

The original note refers to antibodies against central or peripheral nerve proteins, but classic GBS is fundamentally a disease of the peripheral nervous system.

The affected structures include:

Peripheral motor nerves.

Sensory nerves.

Spinal nerve roots.

Cranial nerves.

The brain and spinal cord themselves are not the primary sites of injury.

3. AIDP

Acute inflammatory demyelinating polyneuropathy is the classic demyelinating form of GBS.

Immune-mediated injury damages the myelin surrounding peripheral nerves.

This causes:

Slowing of nerve conduction.

Conduction block.

Temporal dispersion.

The result is progressive weakness and loss of reflexes.

4. Axonal Variants

Not all GBS is demyelinating.

Important variants include:

Acute motor axonal neuropathy, AMAN.

Acute motor and sensory axonal neuropathy, AMSAN.

These forms involve axonal injury rather than primarily myelin damage.

Therefore:

GBS is the overall syndrome; AIDP is one important subtype.

5. Ascending Symmetrical Weakness

The classic presentation is rapidly progressive symmetrical weakness beginning in the legs and ascending upward.

Patients may initially notice:

Difficulty climbing stairs.

Difficulty standing from a chair.

Leg heaviness.

Unsteady walking.

The weakness may then spread to:

Thighs.

Trunk.

Upper limbs.

Bulbar and respiratory muscles.

6. Paralysis

In severe disease, weakness can progress to flaccid paralysis.

Because the disorder can worsen over hours or days, patients require close monitoring even if weakness initially appears mild.

Some patients may lose the ability to:

Walk.

Stand.

Lift the arms.

Swallow effectively.

Breathe independently.

7. Hyporeflexia and Areflexia

One of the most characteristic examination findings is:

Reduced or absent deep tendon reflexes.

The ankle jerks are often lost early.

Reflex abnormalities occur because peripheral nerve and nerve-root conduction is impaired.

Therefore, the classic combination is:

Progressive symmetrical weakness + hyporeflexia/areflexia.

8. Sensory Symptoms

Patients often report:

Paraesthesiae.

Tingling.

Pins and needles.

Numbness.

These sensory symptoms may begin in the feet and hands.

However, objective sensory loss is often relatively mild compared with the degree of motor weakness.

9. Pain

Pain is common and may be under-recognised.

Patients can develop:

Back pain.

Radicular pain.

Deep aching muscular pain.

Neuropathic burning pain.

Pain can sometimes precede obvious weakness.

10. Cranial Nerve Involvement

Cranial nerve involvement is common.

The facial nerves are particularly frequently affected, and weakness may be bilateral.

Patients may develop:

Facial weakness.

Difficulty closing the eyes.

Bulbar weakness.

Dysphagia.

Dysarthria.

The traditional figure of around half of patients developing some cranial nerve involvement is a reasonable teaching approximation, although the exact frequency varies between series and GBS subtypes.

11. Bulbar Weakness

Involvement of the lower cranial nerves can impair swallowing and airway protection.

Patients may develop:

Weak voice.

Dysarthria.

Dysphagia.

Choking.

Aspiration risk.

Bulbar weakness also increases concern for impending respiratory deterioration.

12. Respiratory Muscle Weakness

Respiratory involvement is one of the most dangerous complications of GBS.

Weakness may affect:

Diaphragm.

Intercostal muscles.

Accessory respiratory muscles.

A patient can deteriorate quickly and may require mechanical ventilation.

Importantly, respiratory muscle weakness may progress before severe abnormalities appear on routine oxygen saturation.

13. Autonomic Dysfunction

GBS can affect autonomic nerve fibres and produce potentially dangerous cardiovascular instability.

Manifestations include:

Tachycardia.

Bradycardia.

Marked fluctuations in blood pressure.

Cardiac arrhythmias.

Urinary retention.

Ileus.

Abnormal sweating.

Because severe autonomic instability can cause sudden complications, monitoring is essential.

14. Preceding Infection

A large proportion of patients report an infection in the preceding days or weeks.

The most strongly established infectious trigger is:

Campylobacter jejuni.

Other recognised triggers include:

Cytomegalovirus.

Epstein–Barr virus.

Mycoplasma pneumoniae.

Influenza and other respiratory infections.

Other viral infections can also precede GBS.

15. Campylobacter jejuni

Campylobacter jejuni is one of the most important associations.

It commonly causes a diarrhoeal illness before the neurological symptoms begin.

Certain bacterial surface structures resemble peripheral nerve gangliosides, leading to molecular mimicry and production of cross-reactive antibodies.

This association is particularly strong with some axonal variants of GBS.

16. Time Course

GBS is an acute disorder.

Weakness usually progresses over:

Hours to days, and up to several weeks.

By definition, progression to the worst point generally occurs within 4 weeks.

If weakness continues to progress for substantially longer, alternative diagnoses such as chronic inflammatory demyelinating polyneuropathy should be considered.

17. CSF Findings

Lumbar puncture classically demonstrates:

Raised CSF protein with a normal or only mildly increased white cell count.

This is called:

Albuminocytologic dissociation.

It reflects increased protein from inflamed nerve roots without a major inflammatory cellular response in the CSF.

18. Albuminocytologic Dissociation

The characteristic pattern is:

High protein + few or no white cells.

This finding strongly supports GBS in the appropriate clinical context.

However, CSF protein may still be normal early in the illness, particularly during the first several days.

Therefore:

A normal early lumbar puncture does not exclude GBS.

19. CSF White Cell Count

A substantially increased CSF white cell count is not typical.

If there is marked pleocytosis, clinicians should consider alternative diagnoses such as:

Infectious polyradiculitis.

HIV-related disease.

Lyme disease.

Other inflammatory or infectious conditions.

20. Nerve Conduction Studies

Nerve conduction studies and EMG help confirm peripheral nerve involvement.

In AIDP, nerve conduction studies may show:

Slowed conduction velocity.

Prolonged distal motor latencies.

Prolonged or absent F waves.

Conduction block.

Temporal dispersion.

These findings support a demyelinating neuropathy.

21. Axonal Study Patterns

In AMAN or AMSAN, conduction studies may instead show evidence of axonal loss.

Therefore, not every patient with GBS will show the same classic demyelinating pattern.

This is another reason why GBS should not be equated completely with AIDP.

22. Autoantibodies

Certain antiganglioside antibodies may be detectable.

Examples include:

Anti-GM1 antibodies.

Anti-GD1a antibodies.

Anti-GQ1b antibodies.

However, routine antibody testing is not required to diagnose typical GBS.

The clinical pattern, CSF findings, and neurophysiology are usually more important.

23. Anti-GQ1b Antibodies

Anti-GQ1b antibodies are strongly associated with Miller Fisher syndrome, a GBS variant.

Miller Fisher syndrome classically presents with:

Ophthalmoplegia.

Ataxia.

Areflexia.

This is a useful high-yield association.

24. Respiratory Monitoring

Because deterioration can occur quickly, respiratory function must be monitored closely.

A commonly used bedside measurement is:

Forced vital capacity, FVC.

Serial measurements are more useful than a single value because the trend shows whether respiratory muscle weakness is progressing.

25. Frequency of FVC Monitoring

The original note recommends 4-hourly FVC, which reflects the need for close observation in patients at risk.

The exact frequency depends on:

Severity of weakness.

Rate of progression.

Bulbar involvement.

Current respiratory measurements.

Patients with rapidly worsening disease may need even more frequent respiratory assessment in a high-dependency or intensive care setting.

26. Features Suggesting Impending Ventilatory Failure

Warning signs include:

Rapidly declining FVC.

Weak cough.

Difficulty counting in one breath.

Bulbar weakness.

Use of accessory respiratory muscles.

Orthopnoea.

Inability to clear secretions.

Rapid progression of limb weakness.

These findings should prompt urgent critical-care assessment.

27. Intravenous Immunoglobulin

Intravenous immunoglobulin, IVIG, is one of the main disease-modifying treatments.

It modifies the pathological immune response and can shorten recovery when given appropriately.

A standard course is usually delivered over several days.

28. Plasma Exchange

Plasma exchange, or plasmapheresis, is also effective.

It removes circulating pathogenic antibodies and other immune factors.

Both:

IVIG

and

Plasma exchange

are accepted effective treatments.

They generally have comparable efficacy when used appropriately.

29. IVIG and Plasma Exchange Are Alternatives

These treatments are usually regarded as alternative first-line immunotherapies, rather than therapies routinely combined together.

Giving plasma exchange immediately after IVIG can remove the administered immunoglobulin and is generally not useful as a routine strategy.

30. Corticosteroids

An important examination point is:

Corticosteroids are not an effective routine treatment for GBS.

This distinguishes GBS from several other autoimmune neurological disorders.

31. Mechanical Ventilation

Patients with severe respiratory weakness may require:

Endotracheal intubation and mechanical ventilation.

Early recognition is important because emergency intubation in a patient with severe bulbar and respiratory weakness carries additional risk.

Respiratory support is therefore a major part of GBS management.

32. Supportive Care

Supportive treatment is crucial because neurological recovery may take weeks or months.

Management includes:

DVT prevention.

Pressure-area care.

Pain control.

Physiotherapy.

Nutrition.

Swallowing assessment.

Bladder and bowel management.

Cardiac and blood-pressure monitoring.

33. Rehabilitation

As nerve function recovers, patients may require prolonged rehabilitation.

This can involve:

Physiotherapy.

Occupational therapy.

Mobility aids.

Muscle strengthening after recovery begins.

Psychological support.

Fatigue may persist even after substantial motor recovery.

34. Prognosis

Most patients eventually recover substantially, but recovery can be slow.

Some patients are left with:

Residual weakness.

Neuropathic pain.

Fatigue.

Difficulty walking.

A minority develop severe permanent disability or die from complications such as respiratory failure, infection, or autonomic instability.

35. Guillain–Barré Syndrome – Note Form

Disease: acute immune-mediated polyradiculoneuropathy.

Most common classic subtype: AIDP.

Main pathology in AIDP: autoimmune demyelination of peripheral nerves and nerve roots.

Other forms: axonal variants such as AMAN and AMSAN.

Typical presentation: ascending symmetrical weakness.

Reflexes: reduced or absent.

Sensory symptoms: paraesthesiae and mild numbness.

Severe progression: flaccid paralysis.

Cranial nerves: commonly involved, especially bilateral facial weakness.

Bulbar involvement: dysphagia and aspiration risk.

Autonomic dysfunction: arrhythmias, BP instability, urinary retention and ileus.

Major infectious trigger: Campylobacter jejuni.

Other triggers: CMV, EBV, Mycoplasma and other infections.

CSF: raised protein with normal or mildly raised cells.

Term: albuminocytologic dissociation.

Nerve conduction in AIDP: slowed conduction, prolonged latencies, conduction block and prolonged/absent F waves.

Antibodies: antiganglioside antibodies may occur but are not required for routine diagnosis.

Respiratory monitoring: serial FVC and close clinical observation.

Treatment: IVIG or plasma exchange.

Respiratory failure: mechanical ventilation when required.

Steroids: not routinely effective.

36. Characteristic Examination Pattern

The classic clinical pattern is:

Ascending symmetrical weakness + areflexia/hyporeflexia + relatively mild sensory symptoms.

If severe, add:

Facial/bulbar weakness + autonomic instability + respiratory muscle weakness.

This combination should immediately raise suspicion for GBS.

Key Clinical Pattern

Think of Guillain–Barré syndrome as:

Recent infection → autoimmune peripheral nerve injury → rapidly ascending symmetrical weakness + absent reflexes.

The high-yield diagnostic pattern is:

Weakness + areflexia + CSF high protein with few cells + abnormal nerve conduction studies.

The major danger is:

Respiratory failure + autonomic instability.

The main treatments are:

IVIG OR plasma exchange + intensive supportive and respiratory care when required.

And remember:

GBS affects the peripheral nervous system, not primarily the central nervous system.